Brokerages Expect Lineage Cell Therapeutics (NASDAQ:LCTX) Will Post Earnings of -$0.05 Per Share

Equities research analysts expect Lineage Cell Therapeutics (NASDAQ:LCTX) to report ($0.05) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have made estimates for Lineage Cell Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). Lineage Cell Therapeutics reported earnings per share of ($0.07) during the same quarter last year, which would indicate a positive year-over-year growth rate of 28.6%. The firm is scheduled to issue its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Lineage Cell Therapeutics will report full-year earnings of ($0.06) per share for the current fiscal year, with EPS estimates ranging from ($0.10) to $0.00. For the next financial year, analysts forecast that the business will report earnings of ($0.25) per share, with EPS estimates ranging from ($0.36) to ($0.14). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Lineage Cell Therapeutics.

Lineage Cell Therapeutics (NASDAQ:LCTX) last posted its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $0.78 million for the quarter, compared to the consensus estimate of $1.04 million.

Several equities analysts have weighed in on LCTX shares. Maxim Group set a $3.00 target price on shares of Lineage Cell Therapeutics and gave the company a “buy” rating in a report on Friday, August 9th. Chardan Capital reiterated a “buy” rating on shares of Lineage Cell Therapeutics in a report on Thursday, August 22nd.

NASDAQ:LCTX traded up $0.01 on Tuesday, hitting $0.94. The stock had a trading volume of 1,903 shares, compared to its average volume of 660,860. The stock has a fifty day moving average price of $0.97. Lineage Cell Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.28.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.

Featured Article: What is an investor looking for in an SEC filing?

Get a free copy of the Zacks research report on Lineage Cell Therapeutics (LCTX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Lineage Cell Therapeutics (NASDAQ:LCTX)

Receive News & Ratings for Lineage Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lineage Cell Therapeutics and related companies with's FREE daily email newsletter.